Compare Amgen, Inc. (AMGN) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs KB Financial Group, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while KB Financial Group, Inc. trades at $125 (market cap $42.55B). The key difference: Amgen, Inc. is far larger — about 4.6× KB Financial Group, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | KB | |
|---|---|---|
Market Cap | $196.12B | $42.55B |
Sector | Health | Financials |
52-Week High | $388.16 | $123.19 |
52-Week Low | $271.18 | $77.50 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KB Financial Group (KB) trades at $123.19, up 6.78% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals from moving averages, though oscillators suggest caution with RSI near overbought levels. Fundamentally, revenue grew to $21.23T in 2025 with a net income margin of 27.82%, supported by diversification into non-banking segments. Analyst sentiment is mixed with a 33% buy rating, while recent news highlights dividend potential and non-banking growth.
The outlook for KB remains positive due to earnings growth and strategic diversification, but risks include reliance on interest income and macroeconomic sensitivity. Near-term resistance at $121 could limit upside, while support at $112 provides a cushion. Institutional holdings and dividend focus offer stability, yet investors should monitor interest rate impacts and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
